Insider filing
Traded Mar 3 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Feb 26, 2026 · Filed Feb 27, 2026
Idexx Laboratories's Executive Vice President sold $1.78M of Idexx Laboratories shares. The filing does not indicate a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$1,781,531
Shares × reported transaction price
24 days after results of Feb 2, 2026, 68 days before results of May 5, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $660.71 on Feb 26, 2026, 83% above its 52-week low and 14% below its high, after a 7% drop over the previous 30 trading days
52-week range $361.04 (Apr 8, 2025) to $766.68 (Nov 25, 2025), 74% of the way up, from 251 adjusted closes. 30 trading days earlier: $714.04 on Jan 13, 2026. Describes the past only, not a forecast
RSI 53, 5% above its 200-day average, 2% under its 50-day average, 14% below the 52-week high, 20-day volatility 34% a year, against the S&P 500: −4 points over 1 month, −15 points over 3 months, −4 points over 6 months
From the adjusted closes up to Feb 26, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
Nimrata Hunt is named in IDXX's executive-change filing of Mar 24, 2026, 26 days after this trade: "On March 24, 2026, IDEXX Laboratories, Inc. (“IDEXX”) and Nimrata Hunt, PhD, Executive Vice President, Global Strategy and Commercial, mutually agreed that Dr. Hunt will cease serving in her current role effective on…"
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −4.1% | −1.2% | −2.9% |
| 30 days | −11.3% | −4.5% | −6.8% |
| 90 days | −11.0% | +10.5% | −21.5% |
| 180 days | −12.6% | +11.8% | −24.3% |
Past results only. Not a forecast.
Insider filing
Traded Mar 3 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Insider filing
Traded Mar 3 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Insider selling
Named in an 8-K 21 days laterTraded Mar 3 · filed 2 days laterNot reported under a pre-arranged trading plan
Idexx Laboratories's Executive Vice President sold $1.12M of Idexx Laboratories shares. The filing does not indicate a pre-arranged trading plan.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
The company's last weighty Form 8-K report up to this date: changed a top executive or board member, 13 days earlier (Feb 13, 2026). The first one after it: changed a top executive or board member, 26 days later (Mar 24, 2026).